It appears at least 2 sharks are working together.. Shark (1) dispose those shares due T+3 bought last Wed when price shoot up suddenly from 0.135... then the Shark (2) bought it so that the price will not drop below 0.15... Shark (1) has too many shares bought previously due T+2 and T+3 with average buy price around 0.16... cannot wait for ikan bilis to come in so the first shark need to call in the Shark (2) to help and wallop their share first...
the game will continue for Shark (2) and probably with Shark (1) help again.. they might push the price lower (to get lower average price) or try to push the price higher (higher average sell price).... the final strategy depends on whether they manage to attract more ikan bilis or even new Sharks to join in.
We refer to our announcements dated 25 January 2017, 2 February 2017, 13 February 2017, 15 June 2017, 16 August 2018, 25 October 2018, 5 March 2019, 31 May 2019, 11 October 2019, 4 November 2019, 13 November 2019, 12 December 2019 and 12 February 2020, of which the abbreviations and definitions used herein shall have the same meanings as defined in the previous announcements.
The Board of Directors wishes to announce that the Kuala Lumpur High Court has fixed 3 August 2020 for the Decision.
Why KPJ is next gem for post covid-19? Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71. Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.
There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing. 1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27. 2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect. 3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.
PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019. The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.
PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.
Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.
Shark (2) is still in PDZ... they will do something or waiting for Shark (1) to come back from XOX and wallop Shark (2) shares bought yesterday from Shark (1)..
interesting to see xox share movement.. exactly what happened to PDZ last week.... fake buying Q then bulk dispose by cruel shark.. Shark(1) still swimming there... not sure when they will be back to PDZ.
maybe not today, Shark (1) is busy at xox... Shark (2) needs help from Shark (1).. believe Shark (2) not only Q at 0.155 but also Q for selling at 0.165 and above.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
mushroom
664 posts
Posted by mushroom > 2020-07-27 16:26 | Report Abuse
This is always the pattern to create false perception that sellers are fewer than buyers... bilis will tend to buy at "sell" price